S. Remick

C. Hardy, P. Bottomley, H. Westervelt, 1995, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

The evolving role of statins in hematopoietic stem and progenitor cell transplantation.

S. Remick, L. Gibson, M. Hamadani, 2011, American journal of blood research.

Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.

W. Petros, S. Remick, L. Gibson, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer.

S. Remick, J. Horton, J. Ruckdeschel, 1996, American journal of clinical oncology.

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

J. Doroshow, C. Takimoto, J. Grem, 2007, Clinical Cancer Research.

Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy

M. Fischl, S. Follansbee, S. Remick, 1993, Annals of Internal Medicine.

Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study

P. LoRusso, S. Remick, F. Fox, 2014, Investigational New Drugs.

Extrapulmonary Small‐Cell Carcinoma: A REVIEW OF THE LITERATURE WITH EMPHASIS ON THERAPY AND OUTCOME

S. Remick, Carbone Pp, Hafez Gr, 1987, Medicine.

Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC).

M. Cooney, S. Remick, S. Agarwala, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.

J. Abraham, S. Remick, L. Gibson, 2011, Hematology/oncology and stem cell therapy.

Phase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.

J. Willson, A. Benson, S. Remick, 1989, Cancer research.

Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer

N. Berger, C. Hoppel, A. Dowlati, 2000, Cancer Chemotherapy and Pharmacology.

Primary Central Nervous System Lymphoma in Patients with and without the Acquired Immune Deficiency Syndrome: A Retrospective Analysis and Review of the Literature

R. Haase, S. Remick, J. Ruckdeschel, 1990, Medicine.

Barriers to recruitment of rural patients in cancer clinical trials.

J. Abraham, S. Remick, S. Virani, 2008, Journal of oncology practice.

Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung.

J. Willson, S. Remick, A. Neville, 1987, Cancer treatment reports.

Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (HSP90), in patients with advanced solid tumors: Final results.

S. Ramalingam, C. Erlichman, M. Egorin, 2007 .

Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma.

J. Jett, A. Dowlati, S. Remick, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multi-Institutio nal P hase I /II T rial o f P aclitaxel, Cisplatin, a nd E toposide W ith C oncurrent R adiation f or Limited-Stage S mall-Cell L ung C arcinoma

J. Jett, A. Dowlati, S. Remick, 2000 .

Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.

C. Whitacre, J. Jacobberger, A. Murgo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, ESMO Open.

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.

F. Khuri, A. Gramza, B. Haugen, 2014, Thyroid : official journal of the American Thyroid Association.

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.

P. Fu, M. Cooney, A. Dowlati, 2009, Thyroid : official journal of the American Thyroid Association.

AIDS-associated cancer in developing nations

S. Remick, M. W. Otieno, J. Orem, 2004, Current opinion in oncology.

Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.

J. V. Von Roenn, J. Holden-Wiltse, S. Shriver, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma.

S. Remick, J. Horton, J. Ruckdeschel, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-AIDS-defining cancers.

S. Remick, 1996, Hematology/oncology clinics of North America.

Extrapulmonary Small‐Cell Carcinoma: A REVIEW OF THE LITERATURE WITH EMPHASIS ON THERAPY AND OUTCOME

P. Carbone, S. Remick, G. Hafez, 1987, Medicine.

Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

S. K. Szabo, G. Wood, Lili Liu, 2012, Archives of dermatology.

O6-benzylguanine and BCNU in multiple myeloma: a phase II trial

Lili Liu, P. Fu, S. Remick, 2007, Cancer Chemotherapy and Pharmacology.

Didanosine Compared with Continuation of Zidovudine in HIV-infected Patients with Signs of Clinical Deterioration While Receiving Zidovudine

A. Cross, D. Peterson, I. Frank, 1994, Annals of Internal Medicine.

Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.

W. Wilson, J. Sparano, L. Ratner, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapeutic Challenges of Aids-related Non-hodgkin's Lymphoma in the United States and East Africa

John L. Johnson, M. Lederman, M. Ghannoum, 2022 .

Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.

T. Kinsella, S. Remick, H. Reynolds, 2009, International journal of radiation oncology, biology, physics.

PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer

H. Riedel, M. Mueller, J. Zhang, 2014, Oncogene.

Capacity building for the clinical investigation of AIDS malignancy in East Africa.

John L. Johnson, M. Lederman, M. Ghannoum, 2005, Cancer detection and prevention.

Prevalence of human herpesvirus 8 DNA sequences in several patient populations

S. Remick, D. Mildvan, B. Poiesz, 1996, Journal of clinical microbiology.

Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment

S. Remick, G. Nagaiah, A. Hossain, 2011, Journal of oncology.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

Pingfu Fu, C. Takimoto, H. Lenz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

J. Wright, P. Fu, A. Dowlati, 2013, Thyroid : official journal of the American Thyroid Association.

A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.

F. Khuri, A. Gramza, B. Haugen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling

M. Krem, W. Tse, L. Kenner, 2016, Oncotarget.

AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis

Y. Rojanasakul, Z. Bago-Horvath, W. Tse, 2015, Oncotarget.

Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma.

S. Remick, H. Wagner, T. Pearce, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AIDS-Associated Burkitt’s Lymphoma

S. Remick, P. Mwamba, 2013 .

Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies

M. Monga, S. Remick, L. Gibson, 2013, Clinical & Experimental Metastasis.

S. Remick, P. Loehrer, Scot C Remick, 2012, Lymphoma.

Lung cancer in patients with HIV-infection.

R. Vyzula, S. Remick, Rostislav Vyzula, 1996, Lung cancer.

Breast cancer in a man with human immunodeficiency virus infection.

S. Remick, A. Boguniewicz, T. Nazeer, 1997, Mayo Clinic proceedings.

Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.

John L. Johnson, M. Lederman, L. Ayers, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study.

L. Kalish, M. Oken, S. Remick, 1993, Journal of Clinical Oncology.

Combretastatin A4 phosphate: a novel vascular disrupting agent.

S. Remick, G. Nagaiah, 2010, Future oncology.

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.

S. Ramalingam, C. Erlichman, M. Egorin, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of daily lenalidomide and docetaxel given every three weeks in patients with advanced solid tumors

M. Cooney, S. Remick, S. Krishnamurthi, 2007 .

Community oncologists’ perceptions and utilization of large-panel genomic tumor testing

Karen E. Rasmussen, J. Roberts, M. Hall, 2021, BMC Cancer.

EGFR inhibition in non-small cell lung cancer: current evidence and future directions

A. Chi, S. Remick, W. Tse, 2013, Biomarker Research.

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning

C. Hofmeister, R. Garzon, G. Phillips, 2011, Hematological oncology.

Metronomic Therapy for HIV-Associated Malignancies

S. Remick, R. Rochford, 2010 .

PSP94, an upstream signaling mediator of prostasin found highly elevated in ovarian cancer

H. Riedel, M. Mueller, J. Zhang, 2014, Cell Death and Disease.

Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin

M. Mueller, J. Zhang, S. Remick, 2014, Cell Death and Disease.

Developing Clinical Strength-of-Evidence Approach to Define HIV-Associated Malignancies for Cancer Registration in Kenya

L. Ayers, M. Gurka, S. Remick, 2014, PloS one.

A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies

S. Ramalingam, M. Egorin, S. Remick, 2008, Clinical Cancer Research.

Solid tumors in HIV-infected patients other than AIDS-defining neoplasms.

S. Remick, A. Boguniewicz, B. Wolf, 1993, Advances in experimental medicine and biology.

A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function.

C. Takimoto, J. Kolesar, J. Wright, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

J. Doroshow, C. Takimoto, J. Grem, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma

M. Schluchter, A. Dowlati, S. Remick, 2009, Cancer Chemotherapy and Pharmacology.

A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers

J. Jesberger, N. Ziats, B. Overmoyer, 2009, Clinical Cancer Research.

Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.

A. Dowlati, V. Makkar, S. Remick, 2001, Lung cancer.

Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin

J. Lewin, J. Duerk, J. Jesberger, 2007, Clinical Cancer Research.

Drug Insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery

M. Cooney, S. Remick, S. Bhakta, 2006, Nature Clinical Practice Oncology.

Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study

J. Vulule, G. Buckle, S. Remick, 2016, International journal of cancer.

A Vasculature-Targeting Regimen of Pre-Operative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer:

J. Jesberger, N. Ziats, B. Overmoyer, 2010 .

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis

A. Schmaier, A. Narayan, M. Cooney, 2007, Current opinion in hematology.

Combining Clinical, Pathological, and Demographic Factors Refines Prognosis of Lung Cancer: A Population-Based Study

S. Remick, N. Guo, Joseph Putila, 2011, PloS one.

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment

C. Takimoto, S. Remick, C. Sweeney, 2010, Cancer Chemotherapy and Pharmacology.

Surrogate Markers in Oncology Practice and Anticancer Drug Development: Lessons Learned from Antiretroviral Therapy?

S. Remick, 2004, Cancer investigation.

Stroke Mortality in Kenya's Public Tertiary Hospitals: A Prospective Facility-Based Study

S. Remick, J. Mbui, L. Kaduka, 2018, Cerebrovascular Diseases Extra.

A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors

A. Tolcher, E. Ashton, M. Cooney, 2011, Cancer Chemotherapy and Pharmacology.

Metastatic breast cancer in a young patient seropositive for human immunodeficiency virus.

S. Remick, J. Ruckdeschel, J. McSharry, 1991, Journal of the National Cancer Institute.

Disability-Adjusted Life-Years Due to Stroke in Kenya

S. Remick, J. Mbui, L. Kaduka, 2019, Neuroepidemiology.

Factors Influencing Adherence to Mammography Screening Guidelines in Appalachian Women Participating in a Mobile Mammography Program

Suresh Madhavan, Traci LeMasters, Stephenie K. Kennedy, 2012, Journal of Community Health.

Abstract B83: Factors influencing adherence to mammography screening guidelines in Appalachian women participating in a mobile mammography program

Kimberly M. Kelly, Stephenie K. Kennedy, S. Remick, 2011 .

Declining mammography screening in a state Medicaid Fee-for-Service program: 1999-2008.

S. Remick, S. Madhavan, A. Bhanegaonkar, 2012, Journal of women's health.

Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program.

S. Remick, S. Madhavan, A. Bhanegaonkar, 2011, Journal of women's health.

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

M. Maitland, G. Bakris, H. Black, 2010, Journal of the National Cancer Institute.

Strategies of Dose Escalation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer: Image Guidance and Beyond

M. Monga, J. Welsh, O. Oduntan, 2014, Front. Oncol..

Bendamustine-Associated Hemolytic Anemia

S. Remick, A. Kanate, A. Cumpston, 2009, The Annals of pharmacotherapy.

Extra-pleural pneumonectomy in the setting of tri-modality therapy for patients with malignant pleural mesothelioma.

Z. Liao, A. Chi, N. Nguyen, 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Sorafenib and thyroid cancer

M. Monga, S. Remick, Jessica Perini, 2014, Expert review of endocrinology & metabolism.

A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced Biliary Tree Carcinoma

S. Mani, S. Remick, H. Kindler, 2004, American journal of clinical oncology.

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.

J. Willson, M. Egorin, D. Trump, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, Tolerability, and Pharmacology of Bortezomib in Cancer Patients with Renal Failure Requiring Dialysis: Results from a Prospective Phase 1 Study.

C. Takimoto, S. Remick, M. Karol, 2007 .

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

F. Awan, J. Abraham, S. Remick, 2012, Bone Marrow Transplantation.

Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers

A. Chak, C. Hoppel, P. Fu, 2009, Cancer Chemotherapy and Pharmacology.

EGFR inhibition in non-small cell lung cancer: current evidence and future directions

A. Chi, S. Remick, W. Tse, 2013, Biomarker Research.

Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies

M. Monga, S. Remick, L. Gibson, 2014, Clinical & Experimental Metastasis.

Correlations among ERCC 1 , XPB , UBE 2 I , EGF , TAL 2 and ILF 3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer

Yi Guo, E. Reed, W. Petros, 2022 .

Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.

J. Willson, J. Grem, D. Trump, 1989, Cancer research.

A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors

B. Rini, T. Mekhail, M. Cooney, 2007 .

Preliminary Clinical and Pharmacologic Investigation of Photodynamic Therapy with the Silicon Phthalocyanine Photosensitizer Pc 4 for Primary or Metastatic Cutaneous Cancers

M. E. Kenney, N. Oleinick, M. Kenney, 2011, Frontiers in Oncology.

Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC).

B. Overmoyer, P. Fu, S. Remick, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I pharmacokinetic and pharmacodynamic study of SU5416 and Adriamycin in inflammatory breast cancer

J. Lewin, C. Connell, J. Jesberger, 2001 .

Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.

Yi Guo, J. Yu, E. Reed, 2011, Oncology reports.

Chest wall dose assessment in stereotactic ablative radiotherapy delivered with volumetric modulated arc therapy for peripheral lung tumors

M. Monga, A. Chi, N. Nguyen, 2016 .

Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing

C. Takimoto, M. Egorin, A. Murgo, 2004 .

Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease.

P. Fu, S. Remick, J. Orem, 2006, East African Medical Journal.

Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 Study

E. Cesarman, S. Remick, Jeannette Y Lee, 2020, JCO global oncology.

A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors

M. Cooney, A. Dowlati, S. Remick, 2011, Investigational New Drugs.

Stroke distribution patterns and characteristics in Kenya’s leading public health tertiary institutions: Kenyatta National Hospital and Moi Teaching and Referral Hospital

S. Remick, J. Mbui, L. Kaduka, 2018, Cardiovascular journal of Africa.

Clinical characteristics of Burkitt's lymphoma from three regions in Kenya.

S. Remick, M. Wilson, J. Orem, 2006, East African Medical Journal.

in patients with

D. Dawson, J. Yu, J. Pink, 2010 .

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

M. Cooney, A. Dowlati, S. Remick, 2009, Investigational New Drugs.

Comparable Tumor Responses and Acute/Late Normal Tissue Toxicities with Standard Combined Modality Treatment for Anal Squamous Cell Carcinomas in HIV+ and HIV− Patients

T. Kinsella, S. Remick, H. Reynolds, 2005 .

Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC).

P. Fu, M. Cooney, S. Remick, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

J. Bergh, S. Litière, E. Felip, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.

F. Khuri, A. Gramza, B. Haugen, 2014, Thyroid : official journal of the American Thyroid Association.

Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies.

J. Yu, S. Remick, Xuqing Yang, 2014, Anticancer research.

Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.

S. Remick, B. Adhikari, Nonniekaye Shelburne, 2014, Journal of the National Cancer Institute.

Commentary Cancer Treatment–related Cardiotoxicity: Current State of Knowledge and Future Research Priorities

L. Minasian, Myrtle A. Davis, T. Force, 2022 .

Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC).

M. Cooney, S. Remick, J. Bokar, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

S. Litière, J. Bogaerts, Y. Ohe, 2016, ESMO Open.

Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa.

John L. Johnson, M. Lederman, M. Ghannoum, 2002, Journal of the National Cancer Institute.

A comparative investigation of methods for longitudinal data with limits of detection through a case study

P. Fu, S. Remick, J. Orem, 2016, Statistical methods in medical research.

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning

C. Hofmeister, R. Garzon, G. Phillips, 2011, Hematological oncology.

S. Remick, B. Dezube, N. Azarnia, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN).

A. Argiris, C. Hoppel, M. Cooney, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel agents for the treatment of advanced kidney cancer.

N. Vogelzang, M. Cooney, S. Remick, 2004, Clinical advances in hematology & oncology : H&O.